SCHEMBL2406368

SCHEMBL2406368

FC(F)(F)c1cccc(-c2cnccn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.54
NPY5R Q15761 1/20 0.52
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
CASP1 P29466 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
KMO O15229 2/20 0.50
PIM1 P11309 1/20 0.50
P4HB P07237 1/20 0.49
SCN2A Q99250 2/20 0.49
GRIN1 Q05586 1/20 0.48
GRIN2B Q13224 1/20 0.48
TGFBR1 P36897 1/20 0.48
KDM1A O60341 1/20 0.48
MAOB P27338 1/20 0.48
CTSS P25774 1/20 0.48
ABL1 P00519 1/20 0.47
EPHX2 P34913 1/20 0.47
PIM2 Q9P1W9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28429357 0.98 IDO1 (0.53) IDO1NPY5RALOX15TSHRCASP1
SCHEMBL4404396 0.83 KIF11 (0.57) PIM1CTSSABL1PIM2KIF11
SCHEMBL21290740 0.80 PIM2 (0.55) KMOPIM1ABL1PIM2ALDH1A1
SCHEMBL18292661 0.80 PIM1 (0.51) IDO1NPY5RALOX15TSHRCASP1
SCHEMBL4025464 0.79 TGFBR1 (0.60) IDO1NPSR1KMOSCN2ATGFBR1
SCHEMBL29979429 0.79 TGFBR1 (0.60) IDO1NPSR1KMOSCN2ATGFBR1
SCHEMBL2858005 0.79 KIF11 (0.55) NPY5RTGFBR1KDM1AMAOBABL1
SCHEMBL4033214 0.78 TGFBR1 (0.59) IDO1NPSR1KMOSCN2ATGFBR1
SCHEMBL31140245 0.77 IDO1 (0.50) IDO1KMOPIM1TGFBR1ABL1
SCHEMBL10940225 0.77 NPY5R (0.64) IDO1NPY5RTSHRPIM1GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111303043-A Preparation method of flibanserin hydrochloride 武汉万知化工医药有限公司 2020-06-19 CN claimed
CN-111303043-A Preparation method of flibanserin hydrochloride 武汉万知化工医药有限公司 2020-06-19 CN disclosed
CN-111303043-A Preparation method of flibanserin hydrochloride 武汉万知化工医药有限公司 2020-06-19 CN disclosed
EP-3057963-B1 PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INT (DE) 2019-06-19 EP disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
US-9233953-B2 Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-12 US disclosed
WO-2015055698-A1 PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-23 WO disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-16 US disclosed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105397-A1 Piperazine derivatives and the use thereof as medicament SLC6A7, SLC7A11, SLC7A1 IDO1 874/4885NPY5R 2110/4885ALOX15 999/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 IDO1 993/4885NPY5R 42/4885ALOX15 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.